Dr. James V. A. Abbey, Ph.D., MBA
Dr. James Abbey is the Director for Global & Corporate Partnerships for The Texas A&M University System. In this role, he holds the purview of research at Texas A&M-Galveston, Texas A&M–Corpus Christi, Texas A&M-Kingsville and Texas A&M International-Laredo; in addition to Texas A&M AgriLife Research & Extension, Texas A&M Health Science Centers in College Station and McAllen, Institute for Bio-science & Technology (IBT) in Houston. Dr. Abbey played a pivotal role in securing the strategic collaborative engagements with IBM, US Army Reserve Corp, Trail Head Healthcare and ABENGOA ESP and OvaGene Dianostics.
Previously, Dr Abbey was International Strategic Collaborations Adviser and Director of the Texas/UK Collaborative & International Collaboration at Swansea University in Wales, United Kingdom. In his role at Swansea University, Dr. Abbey helped establish the Center for NanoHealth at Swansea University. He is also one of the driving forces behind the Texas/UK Collaborative & International Collaboration, which involves a consortium of partnering institutions across the United Kingdom and Texas.
The Texas-United Kingdom Collaborative harnessed the collective research experience and ambition of 10 universities and medical colleges in Texas and eight of the UK's top universities. Dr. Abbey also spearheaded the establishment of a joint Ph.D. training program between the Methodist Academy and Swansea University. This formal affiliation agreement brings Ph.D. students to The Methodist Hospital Research Institute for translational research training.
Dr. Abbey’s research interests are in collaborative medical discoveries and translation in the areas of biologics, nanotechnology, and chemistry; involvement in the research of open innovation systems and the effect of collaboration on the development of novel therapeutics; and design of a best-in-class, flexible, biopharmaceutical research, development, training, and production facility focused on hybrid and disposable technologies and equipment for rapid development and production of biopharmaceutical products.
Dr. Abbey’s research goal is to provide rapid, cost-effective FDA, EMEA, and MHRA compliant and scalable manufacturing facilities to enable an array of new products to enter both in vitro and in vivo clinical trials.